• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.

作者信息

Wykoff Charles C, Hariprasad Seenu M

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):302-5. doi: 10.3928/23258160-20150304-01.

DOI:10.3928/23258160-20150304-01
PMID:25835307
Abstract
摘要

相似文献

1
Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.阿柏西普、贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的比较：糖尿病性视网膜病变临床研究网络（DRCR）协议T分析
Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):302-5. doi: 10.3928/23258160-20150304-01.
2
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿：DRCR.net方案T的近期临床相关研究结果
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424.
3
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.阿柏西普、贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的比较：数据外推至临床实践
JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.
4
DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.糖尿病视网膜病变临床研究网络（DRCR）协议-T：协调1年和2年数据以管理糖尿病性黄斑水肿
Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 1;47(4):308-12. doi: 10.3928/23258160-20160324-01.
5
Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.阿柏西普（阿瓦斯汀）与糖尿病性黄斑水肿。在出现明显视力丧失的情况下的首选血管内皮生长因子抑制剂。
Prescrire Int. 2015 Sep;24(163):207.
6
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.玻璃体内注射阿柏西普、贝伐单抗或雷珠单抗治疗伴有视力损害的累及中心的糖尿病性黄斑水肿后持续性黄斑增厚：一项随机临床试验的二次分析。
JAMA Ophthalmol. 2018 Mar 1;136(3):257-269. doi: 10.1001/jamaophthalmol.2017.6565.
7
Intravitreal aflibercept for diabetic macular edema.玻璃体内注射阿柏西普治疗糖尿病性黄斑水肿。
Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8.
8
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.DRCR 视网膜网络初始观察方法治疗中心性糖尿病黄斑水肿和良好视力眼的评估：一项随机临床试验的二次分析。
JAMA Ophthalmol. 2020 Apr 1;138(4):341-349. doi: 10.1001/jamaophthalmol.2019.6035.
9
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿。
N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18.
10
Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.糖尿病视网膜病变临床研究网络近期的临床相关要点。
Curr Opin Ophthalmol. 2018 May;29(3):199-205. doi: 10.1097/ICU.0000000000000472.

引用本文的文献

1
Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema.糖尿病性黄斑水肿从间断治疗转换为连续治疗时黄斑厚度幅度的变化。
BMJ Open Ophthalmol. 2019 Mar 29;4(1):e000271. doi: 10.1136/bmjophth-2019-000271. eCollection 2019.
2
Efficacy and Safety of Intravitreal Conbercept, Ranibizumab, and Triamcinolone on 23-Gauge Vitrectomy for Patients with Proliferative Diabetic Retinopathy.玻璃体内注射康柏西普、雷珠单抗和曲安奈德对增殖性糖尿病视网膜病变患者行23G玻璃体切除术的疗效和安全性
J Ophthalmol. 2018 Jun 25;2018:4927259. doi: 10.1155/2018/4927259. eCollection 2018.
3
Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections.
玻璃体内注射抗VEGF药物治疗糖尿病性黄斑水肿时黄斑收缩及玻璃体视网膜界面改变的定量评估
Graefes Arch Clin Exp Ophthalmol. 2018 Oct;256(10):1801-1806. doi: 10.1007/s00417-018-4042-5. Epub 2018 Jun 20.
4
A novel bispecific molecule delivered by recombinant AAV2 suppresses ocular inflammation and choroidal neovascularization.一种由重组腺相关病毒2型递送的新型双特异性分子可抑制眼部炎症和脉络膜新生血管形成。
J Cell Mol Med. 2017 Aug;21(8):1555-1571. doi: 10.1111/jcmm.13086. Epub 2017 Mar 22.
5
A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy.一项关于康柏西普在增殖性糖尿病视网膜病变玻璃体切除术前预处理的随机对照试验。
J Ophthalmol. 2016;2016:2473234. doi: 10.1155/2016/2473234. Epub 2016 Mar 13.
6
Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications.糖尿病眼部并发症治疗中眼部抗血管内皮生长因子疗法概述
Diabetes Spectr. 2016 Feb;29(1):44-9. doi: 10.2337/diaspect.29.1.44.
7
Aflibercept: A Review of Its Use in Diabetic Macular Oedema.阿柏西普：治疗糖尿病性黄斑水肿的研究进展。
Drugs. 2015 Jul;75(10):1153-60. doi: 10.1007/s40265-015-0421-y.